BiotechTube
Home/Pipeline/BAT5506

BAT5506

Undisclosed Solid Tumors

PreclinicalLicensed to Bayer

Key Facts

Indication
Undisclosed Solid Tumors
Phase
Preclinical
Status
Licensed to Bayer
Company
Compugen

About Compugen

Compugen is a computational discovery-driven biotech focused on identifying and developing first-in-class cancer immunotherapies. Its core asset is the proprietary, AI/ML-powered Unigen™ platform, which integrates multi-omics data to predict novel immune checkpoints and therapeutic targets. The company has successfully translated its computational predictions into a clinical pipeline, with multiple programs in Phase 1/2 development. Its strategy is to advance these assets independently or through strategic partnerships to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Undisclosed Solid Tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
ERAS-113ErascaDiscovery
Multiple ProgramsAktis OncologyDiscovery
Precision DACsPrelude TherapeuticsDiscovery
V2ACT ImmunotherapyGeneluxPhase 1
ATOR-4066Alligator Bioscience ABDiscovery/Preclinical
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical
Albumin Shield™-Enabled OVTheriva BiologicsPreclinical